Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
OSE2101 vaccine shows ‘promising benefit’ in pancreatic cancer trial
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
EU committee recommends Jaypirca for certain leukemia patients
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
Tuspetinib study in newly diagnosed AML moves to higher dose
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…
FDA decision on linvoseltamab in treating RRMM expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
Tuspetinib as part of triple-combo therapy showing potential in AML
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
PAC-MANN blood test shows high accuracy in ID’ing pancreatic cancer
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according to a study led by…
KROS 101 can activate T-cells to target brain cancer in lab studies
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
